title: Sirolimus-eluting coronary stents in small vessels.
abstract: BACKGROUND
  This prospective multicenter study compared angiographic in-lesion late lumen loss in de novo native coronary artery lesions (vessel diameter range 2.25-2.75 mm, length range > or = 15 to < or = 30 mm) 8 months after the implantation of a sirolimus-eluting stent with that of similar vessels with the same drug-eluting stent or a bare stent of the SIRIUS study (historical controls).
  
  
  RESULTS
  One hundred one patients (study group) were matched and compared with 323 patients receiving the bare stent (bare control group) and with 350 receiving the Cypher stent (Cypher control group) in the SIRIUS trial. Mean in-lesion late loss in the study group was lower than that in the bare control group (0.20 versus 0.76 mm, P < .0001) and not inferior to that in the Cypher control group (0.27 mm, P = .3). Adverse event rates (death and myocardial infarction) were similar between groups. At 8 months, target lesion revascularization rates were 0% in the study group, 13.2% in the bare control group (P < .001), and 4.6% in the Cypher control group (P = .03).
  
  
  CONCLUSIONS
  The Cypher Bx Velocity stent was confirmed to be superior to the bare Bx Velocity stent in small coronary vessels in terms of in-lesion late loss 8 months after implantation.
authors.affiliation: Swiss Cardiovascular Center Bern, University Hospital, Bern, Switzerland. bernhard.meier@insel.ch
authors.forename: Bernhard
authors.initials: B
authors.lastname: Meier
authors.forename: Eduardo
authors.initials: E
authors.lastname: Sousa
authors.forename: Giulio
authors.initials: G
authors.lastname: Guagliumi
authors.forename: Frank
authors.initials: F
authors.lastname: Van den Branden
authors.forename: Ehud
authors.initials: E
authors.lastname: Grenadier
authors.forename: Stephan
authors.initials: S
authors.lastname: Windecker
authors.forename: Hans
authors.initials: H
authors.lastname: te Riele
authors.forename: Vasilis
authors.initials: V
authors.lastname: Voudris
authors.forename: Hélène
authors.initials: H
authors.lastname: Eltchaninoff
authors.forename: Bo
authors.initials: B
authors.lastname: Lindvall
authors.forename: David
authors.initials: D
authors.lastname: Snead
authors.forename: Aly
authors.initials: A
authors.lastname: Talen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000000981:diagnostic imaging* / Q000628:therapy*; D017023:Coronary Angiography; D003331:Coronary Vessels / Q000000981:diagnostic imaging*; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology / Q000209:etiology; D020123:Sirolimus / Q000008:administration & dosage* / Q000627:therapeutic use; D015607:Stents / Q000009:adverse effects; D018084:Ultrasonography, Interventional
chemical_list: D020533:Angiogenesis Inhibitors; D020123:Sirolimus